With the availability of long-term survival data from several phase 3 studies evaluating ICI plus chemotherapy in patients with advanced NSCLC, we studied whether there was a difference between the different regimens in treating patients with PD-L1–negative NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.